TRAIL Modulates the Immune System and Protects against the Development of Diabetes

被引:33
作者
Bossi, Fleur [1 ]
Bernardi, Stella [1 ]
Zauli, Giorgio [2 ]
Secchiero, Paola [3 ]
Fabris, Bruno [1 ]
机构
[1] Univ Trieste, Cattinara Univ Hosp, Dept Med Surg & Hlth Sci, I-34100 Trieste, Italy
[2] IRCCS Burlo Garofolo, Inst Maternal & Child Hlth, I-34100 Trieste, Italy
[3] Univ Ferrara, LTTA Ctr, Dept Morphol Surg & Expt Med, I-44100 Ferrara, Italy
关键词
APOPTOSIS-INDUCING LIGAND; C-REACTIVE PROTEIN; T-CELL-ACTIVATION; NF-KAPPA-B; ADIPOSE-TISSUE; INSULIN-RESISTANCE; THYMOCYTE APOPTOSIS; MEDIATED ACTIVATION; ENDOTHELIAL-CELLS; ADIPOCYTE DEATH;
D O I
10.1155/2015/680749
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
TRAIL or tumor necrosis factor (TNF) related apoptosis-inducing ligand is a member of the TNF superfamily of proteins, whose best characterized function is the induction of apoptosis in tumor, infected, or transformed cells through activation of specific receptors. In nontransformed cells, however, the actions of TRAIL are less well characterized. Recent studies suggest that TRAIL may be implicated in the development and progression of diabetes. Here we review TRAIL biological actions, its effects on the immune system, and how and to what extent it has been shown to protect against diabetes.
引用
收藏
页数:12
相关论文
共 107 条
  • [1] Helper T cell anergy: from biochemistry to cancer pathophysiology and therapeutics
    Appleman, LJ
    Tzachanis, D
    Grader-Beck, T
    van Puijenbroek, AAFL
    Boussiotis, VA
    [J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 2001, 78 (12): : 673 - 683
  • [2] Safety and antitumor activity of recombinant soluble Apo2 ligand
    Ashkenazi, A
    Pai, RC
    Fong, S
    Leung, S
    Lawrence, DA
    Masters, SA
    Blackie, C
    Chang, L
    McMurtrey, AE
    Hebert, A
    DeForge, L
    Koumenis, IL
    Lewis, D
    Harris, L
    Bussiere, J
    Koeppen, H
    Shahrokh, Z
    Schwall, RH
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) : 155 - 162
  • [3] To kill a tumor cell: the potential of proapoptotic receptor agonists
    Ashkenazi, Avi
    Herbst, Roy S.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (06) : 1979 - 1990
  • [4] ACE2 deficiency shifts energy metabolism towards glucose utilization
    Bernardi, Stella
    Tikellis, Christos
    Candido, Riccardo
    Tsorotes, Despina
    Pickering, Raelene J.
    Bossi, Fleur
    Carretta, Renzo
    Fabris, Bruno
    Cooper, Mark E.
    Thomas, Merlin C.
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2015, 64 (03): : 406 - 415
  • [5] Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes
    Bernardi, Stella
    Fabris, Bruno
    Thomas, Merlin
    Toffoli, Barbara
    Tikellis, Christos
    Candido, Riccardo
    Catena, Cristiana
    Mulatero, Paolo
    Barbone, Fabio
    Radillo, Oriano
    Zauli, Giorgio
    Secchiero, Paola
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2014, 394 (1-2) : 13 - 20
  • [6] Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus
    Bernardi, Stella
    Norcio, Alessia
    Toffoli, Barbara
    Zauli, Giorgio
    Secchiero, Paola
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (35) : 5759 - 5765
  • [7] TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases
    Bernardi, Stella
    Milani, Daniela
    Fabris, Bruno
    Secchiero, Paola
    Zauli, Giorgio
    [J]. CURRENT DRUG TARGETS, 2012, 13 (09) : 1215 - 1221
  • [8] TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation
    Bernardi, Stella
    Zauli, Giorgio
    Tikellis, Christos
    Candido, Riccardo
    Fabris, Bruno
    Secchiero, Paola
    Cooper, Mark E.
    Thomas, Merlin C.
    [J]. CLINICAL SCIENCE, 2012, 123 (9-10) : 547 - 555
  • [9] State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL
    Bernardi, Stella
    Secchiero, Paola
    Zauli, Giorgio
    [J]. RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2012, 7 (02) : 207 - 217
  • [10] Human CD8+ T cell blasts are more sensitive than CD4+ T cell blasts to regulation by APO2L/TRAIL
    Bosque, A
    Pardo, J
    Martínez-Lorenzo, MJ
    Lasierra, P
    Larrad, L
    Marzo, I
    Naval, J
    Anel, A
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2005, 35 (06) : 1812 - 1821